Literature DB >> 8573016

Early retinal vessel development and iris vessel dilatation as factors in retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) Cooperative Group.

J D Kivlin1, A W Biglan, R A Gordon, V Dobson, R A Hardy, E A Palmer, B Tung, W Gilbert, R Spencer, K P Cheng, E Buckley.   

Abstract

OBJECTIVE: To determine whether the extent of retinal vessel development present on early screening examinations for retinopathy of prematurity has prognostic value?
DESIGN: The prospectively collected data from the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity were used to compare the development of acute retinopathy of prematurity and long-term structural and visual outcomes for eyes with differing extents of retinal vessel development. PATIENT: Study patients had eyes with the following vessel development. In zone I eyes, vessels extended from the disc less than twice the distance from the disc to the macula. In zone II eyes, vessels extended beyond zone I but not to the nasal ora serrata. Transitional eyes had vessels partly in zone I and partly in zone II.
RESULTS: The chance of developing threshold retinopathy of prematurity was inversely related to the early degree of vessel development: 54% for zone I eyes, 25% for transitional eyes, and 8% for zone II eyes. The presence of prominent iris vessels at 34 to 35 weeks of postmenstrual age was associated with increased risk for all three groups; zone I eyes almost always needed treatment (94%). The chance of having an unfavorable anatomic alteration of the posterior fundus, or poor vision at the ages of 1 year and 3 1/2 years, was also inversely related to the degree of early vessel development. Vessel development was an independently important factor even when birth weight, gestational age, and race were considered.
CONCLUSIONS: The degree of early retinal vessel development is a significant predictor of outcome from retinopathy of prematurity. Iris vessel dilatation is an important indication for greater vigilance in following these infants.

Entities:  

Mesh:

Year:  1996        PMID: 8573016     DOI: 10.1001/archopht.1996.01100130144005

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  Alterations of the tunica vasculosa lentis in the rat model of retinopathy of prematurity.

Authors:  Tara L Favazza; Naoyuki Tanimoto; Robert J Munro; Susanne C Beck; Marina Garcia Garrido; Christina Seide; Vithiyanjali Sothilingam; Ronald M Hansen; Anne B Fulton; Mathias W Seeliger; James D Akula
Journal:  Doc Ophthalmol       Date:  2013-06-08       Impact factor: 2.379

2.  Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491.

Authors:  Luca Filippi; Giacomo Cavallaro; Patrizio Fiorini; Marta Daniotti; Valentina Benedetti; Gloria Cristofori; Gabriella Araimo; Luca Ramenghi; Agostino La Torre; Pina Fortunato; Liliana Pollazzi; Giancarlo la Marca; Sabrina Malvagia; Paola Bagnoli; Chiara Ristori; Massimo Dal Monte; Anna Rita Bilia; Benedetta Isacchi; Sandra Furlanetto; Francesca Tinelli; Giovanni Cioni; Gianpaolo Donzelli; Silvia Osnaghi; Fabio Mosca
Journal:  BMC Pediatr       Date:  2010-11-18       Impact factor: 2.125

3.  Treatment of retinopathy of prematurity with topical ketorolac tromethamine: a preliminary study.

Authors:  Medardo Avila-Vazquez; Roque Maffrand; Mirta Sosa; Maria Franco; Beatriz Vaca De Alvarez; Maria Luisa Cafferata; Eduardo Bergel
Journal:  BMC Pediatr       Date:  2004-08-07       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.